Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 T-DM1 in inoperable or recurrent HER2-positive breast cancer
jRCT2080222345Phase 2
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Dec 2013
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab emtansine in breast cancer, sponsored by Chugai Pharmaceutical Co., Ltd.
02
Drugs
trastuzumab emtansine
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2080222345.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080222345.